Sight Diagnostics has reportedly laid off its remaining employees, marking a dramatic collapse for the Israeli blood-testing startup that once raised about $124 million and employed more than 150 people at its peak.
According to Calcalist, the company’s board dismissed the roughly 20 employees who remained at Sight Diagnostics, effectively bringing operations to the brink of closure. The move follows earlier rounds of cuts, including a May 2024 reduction in which the company laid off about 40 employees, or around 30% of its workforce at the time.
Founded in 2011 by Yossi Pollak and Dr. Daniel Levner, Sight Diagnostics developed Sight OLO, a compact blood analyzer designed to deliver complete blood count results from venous or finger-prick blood samples. The company attracted major investors including Koch Disruptive Technologies, Longliv Ventures, CK Hutchison Holdings, and OurCrowd.
Sight’s product achieved notable regulatory progress, including FDA clearance for use in moderate-complexity laboratories in the United States, as well as broader point-of-care approvals in some international markets. However, the company appears to have struggled to convert its technology and regulatory milestones into a sustainable commercial business.
The company’s trajectory underscores the difficulty of scaling medical hardware and diagnostics businesses, where regulatory clearance alone is rarely enough. Companies must also overcome reimbursement hurdles, hospital procurement cycles, workflow integration, service reliability, quality assurance requirements, and competition from entrenched laboratory systems.
Sight Diagnostics declined to comment on the report, according to Calcalist.